🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

782 results for “S.A.” Clear

  1. Placebo for Belimumab Solution for Injection, 200 mg/mL, Benlysta 200 mg solution for injection in pre-filled syringe.

    GlaxoSmithKline Biologicals S.A.

    systemic sclerosis associated interstitial lung disease

    phase 3 small molecule active

    1 trial

  2. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  3. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  4. Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection

    GlaxoSmithKline Biologicals S.A.

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  5. Placebo for Mitapivat, MITAPIVAT

    Pharma Mar S.A.

    Non–Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  6. Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

    Pharma Mar S.A.

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  7. Placebo liquid formulation will be indistinguishable from its tasimelteon counterpart and will be administered in the same way., Tasimelteon

    Pharma Mar S.A.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  8. Placebo matching < Staccato® alprazolam > and without active substance, alprazolam

    Pharma Mar S.A.

    Stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  9. Placebo matching AMX0035, AMX0035

    Pharma Mar S.A.

    Progressive Supranuclear Palsy

    phase 3 small molecule active

    1 trial

  10. Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Pharma Mar S.A.

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  11. Placebo matching REGN7508, REGN7508

    Pharma Mar S.A.

    Cancer-Associated Thrombosis (CAT).

    phase 3 small molecule active

    1 trial

  12. Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized), ustekinumab, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (authorized - MA number: 6697366.00.00), bimekizumab

    Pharma Mar S.A.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  13. Placebo matching to garetosmab, Garetosmab

    Pharma Mar S.A.

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  14. Placebo tablets without active pharmaceutical ingredient closely resembling the imp, Hetrombopag Olamine

    Pharma Mar S.A.

    Chemotherapy induced thrombocytopenia

    phase 3 small molecule active

    1 trial

  15. Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant

    Pharma Mar S.A.

    Trigeminal neuralgia, Trigeminal neuralgia

    phase 3 small molecule active

    1 trial

  16. Placebo to match Linaprazan glurate 50mg, Placebo to match Lansoprazole 30 mg, Linaprazan glurate, LANSOPRAZOLE

    Pharma Mar S.A.

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  17. Placebo to match Paltusotine tablets 20 mg, Paltusotine tablets

    Pharma Mar S.A.

    Acromegaly

    phase 3 small molecule active

    1 trial

  18. Placebo to match paltusotine tablets 20 mg, Paltusotine tablets

    Pharma Mar S.A.

    Acromegaly

    phase 3 small molecule active

    1 trial

  19. Placebo, Atoris, 40 mg, tabletki powlekane

    Bial Portela & Companhia S.A.

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  20. Placebo, Minirin, 4 mikrogramy/ml, roztwór do wstrzykiwań

    Bial Portela & Companhia S.A.

    Rare and ultra-rare glomerulonephritis

    phase 3 small molecule active

    1 trial

  21. Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Pharma Mar S.A.

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  22. Placebo, Paltusotine 40 mg tablets, Paltusotine 40 mg tablets

    Pharma Mar S.A.

    Carcinoid syndrome

    phase 3 small molecule active

    1 trial

  23. Placebo, capsule, ZYTIGA 500 mg film-coated tablets, Prednison acis 5 mg, Tabletten, Fuzuloparib

    Pharma Mar S.A.

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  24. Placebo, oral solution, Maralixibat chloride

    Pharma Mar S.A.

    Cholestatic Pruritus

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources